DETERMINATION OF IN VITRO OUTLET OF LIZINOPRIL CONTAINING MEDICAL PREPARATION ”LIZINOCOR” AND ITS ANALOGUE USING METHOD OF HIGHPERFORMANCE LIQUID CHROMATOGRAPHY

Authors

  • Chikviladze T. ჩიკვილაძე თ.
  • Lashauri N. ლაშაური ნ.
  • Jorjikia M. ჯორჯიკია მ.
  • Chincharadze D. ჭინჭარაძე დ.
  • Otarashvili T. ოთარაშვილი თ.
  • Ioramashvili H. იორამაშვილი ჰ.

DOI:

https://doi.org/10.52340/csw.2015.49.0.137-140

Abstract

ACE Inhibitors represent the first class of anti hypertensive agents that was designed and developed on the basis of a  well-defined physiopathol ogical axis of arterial hypertension, a vascular disorder that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing countries. An angiotensin-converting enzyme (ACE) inhibitor, the  carboxylalkyl compounds derivated  lizinopril  is apharmaceutical  drug,    used primarily for the treatment of hypertension  (elevated blood pressure) and congestive heart failure. Purpose of investigation was – comparison of in vitro outlet of 5 mg tablets of  ”Lizinocor” containing Lizinopril , produced by the Georgian pharmaceutical company “GMP” and its analogue ”Zestril” using method of high-performance liquid chromatography. According to the received results average percent quantity  outlet of ”lizinocor” is 97,65 %, ”Zestril” – 95, 88%;. Inclination in comparison with Zestril is 1,85 %, (norm ± 5 %). ”Lizinocor” 5 mg tablets containing Lizinopril produced by the Georgian pharmaceutical company ”GMP” are characterized by good outlet quality.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

1. Артериальная гипертензия новый взгляд на ингибиторы АПФ [электронный ресурс] / Яблучанский Н.И. // Medicus Amicus - 2007. Режим доступа к журн.:
2. Беликов В.Г. - Фармацевтическая химия. Москва 2007.С 317-321
3. Государственная Фармакопея Российской Федерации. XII 2007 .ст 579-581
4. Григорьев Ю.В. Рациональная антигипе- ртензивная терапия / / ГВМУ МО РФ, ГИУВ МО РФ: Методические рекомендации. - М., 2000.
5. Д.В. Преображенский, Н.И. Некрасова, И.В. Талызина и др Лизиноприл - гидрофильный ингибитор ангиотензинпревращающего фермента длительного действия: особенности клинической фармакологии и диапазон клинического применения “Здоровье Украины” 4 (257) февраль г. c.18
6. British Pharmakopoeia. 2009. P 3509-3513 7. Hernandez Prada J.A., Ferreira A.J., Katovich M.J., Shenoy V., Qi Y., Santos R.A., Castellano R.K., Lampkins A.J., Gubala V., Ostrov D.A., Raizada M.K. Structure–based identification of small–molecule angiotensin–converting enzyme 2 activators as novel antihypertensive agents // Hypertension. 2008. Vol. 51. Ð. 1312–1317. 8.Jamkhandi C.M1, Chandrasekhar Javali2, M.S.Nira- njan//Developed Analytical Methods for Lisinopril- An Ace Inhibitor// Asian Journal of Biochemical and Pharmaceutical Research Issue 2 (Vol. 1) 2011ISSN: 2231-2560
9. Steckelings U.M., Unger T. The renin–angiotensin– aldosterone system; in Mancia G, Grassi G, Kjeldsen S (eds): Manual of Hypertension of The Euro¬pean Society of Hypertension. Abingdon, Informa HealthCare, 20014. Vol. 14. Ð. 110–116.
10. WAEL ABU DAYYIH1*, SARAH ALSAID, MOHAMMED HAMAD2, FAISAL AL AKAYLEH3, EYAD MALLAH1 // DEVELOPMENT AND VALIDATION OF AREVERSE PHASE HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF SOME PRILLS IN DRUG FORMS //International Journal of Pharmacy and Pharmaceutical Sciences Vol 5, Issue 1, 2013 ISSN- 0975-1491
11. http://mis.ge/ka/FindDrug.jspClear=True

Downloads

Published

2019-11-06

How to Cite

ჩიკვილაძე თ. C. T., ლაშაური ნ. L. N., ჯორჯიკია მ. J. M., ჭინჭარაძე დ. C. D., ოთარაშვილი თ. O. T., & იორამაშვილი ჰ. I. H. (2019). DETERMINATION OF IN VITRO OUTLET OF LIZINOPRIL CONTAINING MEDICAL PREPARATION ”LIZINOCOR” AND ITS ANALOGUE USING METHOD OF HIGHPERFORMANCE LIQUID CHROMATOGRAPHY. COLLECTION OF SCIENTIFIC WORKS OF TBILISI STATE MEDICAL UNIVERSITY, 49, 137–140. https://doi.org/10.52340/csw.2015.49.0.137-140

Most read articles by the same author(s)